Isothiazole heterocyclic compound, and preparation method, pharmaceutical composition and application thereof

A technology of isothiazoles and compounds, applied in the field of medicinal chemistry, can solve the problems of being unable to take orally, only injecting or dripping, unstable in the body, etc., and achieve the effect of inhibiting growth and high inhibitory activity

Pending Publication Date: 2022-05-17
INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, monoclonal antibody therapy has its own defects: it is easily decomposed by protease, so it is unstable in the body and cannot be taken orally; it is easy to produce

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Isothiazole heterocyclic compound, and preparation method, pharmaceutical composition and application thereof
  • Isothiazole heterocyclic compound, and preparation method, pharmaceutical composition and application thereof
  • Isothiazole heterocyclic compound, and preparation method, pharmaceutical composition and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0502] Example 1: 1-(3-(2-Chloro-3-(1,4-benzodioxan-6-yl)anilino)isothiazolo[4,5-b]pyrazine-6-idene Methyl)pyrrolidin-3-ol

[0503]

[0504] 3-Hydroxy-5-methylpyrazine-2-carboxamide:

[0505] To the 100mL reaction flask, add glyoxal (40% aqueous solution, 21.6ml, 120mmol) and NaHSO in turn 3 (15.6 g, 150 mmol), start stirring, then slowly add the prepared NaOH aqueous solution (500 mg, 12.5 mmol, 39 ml of water) dropwise to the solution, react at 80 ° C after the dropwise addition, and slowly add 2-aminopropane after the reaction for 1 h Diamide (11.7 g, 100 mmol), continue to react at 80 ° C for 3 h, stop heating, and add NaA after cooling to room temperature C (20.5 g, 250 mmol) and H 2 O 2 (16.4 ml) and stirred at room temperature overnight. The reaction solution was suction filtered to obtain 9.7 g of a pink solid. Yield: 63.4%. 1 H NMR (400MHz, DMSO-d 6 )δ13.40(s,1H),8.64(s,2H),7.39(s,1H),2.21(s,3H).

[0506] 3-Chloro-5-methylpyrazine-2-carbonitrile:

[0507]...

Example Embodiment

[0518] Example 2: 1-(3-(2-Chloro-3-(1,4-benzodioxan-6-yl)anilino)isothiazolo[4,5-b]pyridine-6-methylene yl)pyrrolidin-3-ol

[0519]

[0520] 2-cyano-3-nitro-5-methylpyridine:

[0521] 2-Bromo-3-nitro-5-methylpyridine (1 g, 4.61 mmol) and CuCN (454 mg, 5.07 mmol) were added to the three-necked flask, replaced with argon, and 5 ml of DMF was added to the syringe, and the reaction was carried out at 70° C. for 4 h. Cool to room temperature, add EA / H 2 O (40ml / 20ml), filtered through celite, separated, the organic phase was washed once with 20ml of water, washed once with 20ml of ammonium chloride / ammonia, the aqueous phase was extracted twice with 20ml of EA, the organic phases were combined, and washed with 20ml of saturated brine for 1 and dried over anhydrous sodium sulfate. Evaporated to dryness under reduced pressure, and prepared under medium pressure (PE:EA 4:1-2:1) to obtain 347 mg of a yellow-white solid. Yield: 46.14%. HRMS(ESI)m / z:164.04453[M+H] + . 1 H NMR (...

Example Embodiment

[0535] Example 3: (S)-1-(3-(2-Chloro-3-(1,4-benzodioxan-6-yl)anilino)isothiazolo[4,5-b]pyrazine -6-Methylene)pyrrolidin-3-ol

[0536]

[0537] Use (S)-3-hydroxypyrrolidine instead of racemic 3-hydroxypyrrolidine, the operation is the same as that in Example 1, to obtain (S)-1-(3-(2-chloro-3-(1,4-benzodi) Oxan-6-yl)anilino)isothiazolo[4,5-b]pyrazin-6-methylene)pyrrolidin-3-ol as a yellow solid. HRMS(ESI)m / z:496.11857[M+H] + .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of medicinal chemistry, and discloses an isothiazole heterocyclic compound, and a preparation method, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isothiazole heterocyclic compound as shown in a general formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof and a preparation method thereof, a composition containing one or more of the compounds, and application of the compounds in treatment of diseases related to PD-1/PD-L1 signal pathways, such as cancers, infectious diseases and autoimmune diseases.

Description

[0001] field of invention [0002] The invention belongs to the field of medicinal chemistry, and discloses a class of isothiazolo heterocyclic compounds, a preparation method, a pharmaceutical composition and application thereof. Specifically, it relates to isothiazolo heterocyclic compounds represented by general formula I, pharmaceutically acceptable salts thereof, stereoisomers and preparation methods thereof, compositions containing one or more of these compounds, and such compounds Use in the treatment of diseases related to the PD-1 / PD-L1 signaling pathway, such as cancer, infectious diseases, and autoimmune diseases. [0003] Background of the invention [0004] With the in-depth study of tumor immunity, it has been found that the tumor microenvironment can protect tumor cells from being recognized and killed by the body's immune system, and the immune escape of tumor cells plays a very important role in the occurrence and development of tumors. In 2013, Science magazi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D513/04C07D519/00A61P35/00A61P35/02A61P37/02A61P31/00A61P5/16A61P5/14A61P3/10A61P1/04A61P21/04A61P1/00A61P11/00A61P1/16A61P25/00A61P29/00A61P19/02A61P17/00A61P7/06A61P31/04A61P31/12A61K31/437A61K31/4985
CPCC07D513/04C07D519/00A61P35/00A61P35/02A61P37/02A61P31/00A61P5/16A61P5/14A61P3/10A61P1/04A61P21/04A61P1/00A61P11/00A61P1/16A61P25/00A61P29/00A61P19/02A61P17/00A61P7/06A61P31/04A61P31/12
Inventor 冯志强黄旭鹏陈浩
Owner INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap